Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat

Biochemical Pharmacology

Volumn 82, Issue 9, 2011, Pages 1227-1233

  Peroni, Roxana N ^a,b   Di Gennaro, Stefania S ^a   Hocht, Christian ^b   Chiappetta, Diego A ^a,b   Rubio, Modesto C ^a,b   Sosnik, Alejandro ^a,b   Bramuglia, Guillermo F ^b  

^a National Science Research Council CONICET   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Abcg2; Efavirenz; Hiv; Intestine; Oral bioavailability

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; EFAVIRENZ; FUMITREMORGIN C; GLYCOPROTEIN P;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; DRUG TRANSPORT; GASTROINTESTINAL TRACT; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; INTESTINE WALL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOXAZINES; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 81155159797     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.07.081     Document Type: Article

References (44)

1. B. Gazzard British HIV Association (BHIVA) guidelines for the treatment of HIV infected adults with antiretroviral therapy HIV Med 7 2006 487 496
2. N. Barrueco, I. Castillo, A. Ais, C. Martínez, and M. Sanjurjo Pharmaceutical care program for pediatric patients receiving antiretroviral therapy Farm Hosp 29 2005 367 374 (Pubitemid 43213228)
3. U. Wintergerst, F. Hoffmann, A. Jansson, G. Notheis, K. Huss, and M. Kurowski Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children J Antimicrob Chemother 61 2008 1336 1339 (Pubitemid 351753604)
4. H.J. Scherpbier, V. Bekker, D. Pajkrt, S. Jurriaans, J.M. Lange, and T.W. Kuijpers Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen Pediatrics 119 2007 e705 e715
5. M. Lindenberg, S. Kopp, and J.B. Dressman Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system Eur J Pharm Biopharm 58 2004 265 278 (Pubitemid 39037234)
6. C. Csajka, C. Marzollini, K. Fattinger, L.A. Décosterd, J. Fellay, and A. Telenti Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection Clin Pharmacol Ther 73 2003 20 30 (Pubitemid 36158483)
7. R.E. Aarnoutse, J.M. Schapiro, C.A. Boucher, Y.A. Hekster, and D.M. Burger Therapeutic drug monitoring Drugs 63 2003 741 753
8. R.C. Brundage, F.H. Yong, T. Fenton, S.A. Spector, S.E. Starr, and C.V. Fletcher Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy Antimicrob Agents Chemother 48 2004 979 984 (Pubitemid 38280352)
9. M. Pfister, L. Labbe, S.M. Hammer, J. Mellors, K.K. Bennett, and S. Rosenkranz Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS Clinical Trial Group Study 398 Antimicrob Agents Chemother 47 2003 130 137 (Pubitemid 36070353)
10. C. Marzolini, A. Telenti, L.A. Decosterd, G. Greub, J. Biollaz, and T. Buclin Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients AIDS 15 2001 71 75 (Pubitemid 32055781)
11. M. Nunez, D. Gonzalez de Requena, L. Gallego, I. Jimenez-Nacher, J. Gonzalez-Lahoz, and V. Soriano Higher efavirenz plasma levels correlate with development of insomnia J Acquir Immune Defic Syndr 28 2001 399 400
12. S.R. Rabel, S. Sun, and M.B. Maurin Electronic and resonance effects on the ionization of structural analogues of efavirenz AAPS Pharm Sci Tech 3 2001 E28
13. JZh Gao, M.A. Hussain, R. Motheram, D.A. Gray, I.H. Benedek, and W.D. Fiske Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz) J Pharm Sci 96 2007 2970 2977 (Pubitemid 350221197)
14. G.L. Amidon, H. Lennernäs, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res 12 1995 413 420
15. C. Lipinski Poor aqueous solubility - an industry wide problem in drug discovery Am Pharm Rev 5 2002 82 85
16. D.A. Chiappetta, and A. Sosnik Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs Eur J Pharm Biopharm 66 2007 303 317 (Pubitemid 46756232)
17. D.A. Chiappetta, C. Hocht, C. Taira, and A. Sosnik Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailaibility Nanomedicine 5 2010 11 23
18. D.A. Chiappetta, C. Hocht, C. Taira, and A. Sosnik Oral pharmacokinetics of efavirenz-loaded polymeric micelles Biomaterials 32 2011 2379 2387
19. G. Ramachandran, A.K. Hemanth Kumar, S. Rajasekaran, P. Kumar, K. Ramesh, and S. Anitha CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India Antimicrob Agents Chemother 53 2009 863 868
20. N.Y. Rakhmanina, and J.N. van den Anker Efavirenz in the therapy of HIV infection Expert Opin Drug Metab Toxicol 6 2010 95 103
21. H.J. Ribaudo, H. Liu, M. Schwab, E. Schaeffeler, M. Eichelbaum, and A.A. Motsinger-Reif Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study J Infect Dis 202 2010 717 722
22. E. Ngaimisi, S. Mugusi, O.M. Minzi, P. Sasi, K.D. Riedel, and A. Suda Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients Clin Pharmacol Ther 88 2010 676 684
23. Yenny, Nafrialdi, Z. Djoerban, and R. Setiabudy Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers Int J Clin Pharmacol Ther 49 2011 162 168
24. A. Kwara, M. Lartey, K.W. Sagoe, and M.H. Court Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy AIDS 25 2011 388 390
25. D.W. Haas, L.M. Smeaton, R.W. Shafer, G.K. Robbins, G.D. Morse, and L. Labbe Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study J Infect Dis 192 2005 1931 1942 (Pubitemid 41681891)
26. J. Fellay, C. Marzolini, E.R. Meaden, D.J. Back, T. Buclin, and J.P. Chave Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study Lancet 359 2002 30 36 (Pubitemid 34119193)
27. J.K. Mukonzo, D. Röshammar, P. Waako, M. Andersson, T. Fukasawa, and L. Milani A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans Br J Clin Pharmacol 68 2009 690 699
28. M. Nasi, V. Borghi, M. Pinti, C. Bellodi, E. Lugli, and S. Maffei MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients AIDS 17 2003 1696 1698 (Pubitemid 36951692)
29. R. Winzer, P. Langmann, M. Zilly, F. Tollmann, J. Schubert, and H. Klinker No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment Eur J Med Res 8 2003 531 534
30. J. Weiss, J. Rose, C.H. Storch, N. Ketabi-Kiyanvash, A. Sauer, and W.E. Haefeli Modulation of human BCRP (ABCG2) activity by anti-HIV drugs J Antimicrob Chemother 59 2007 238 245 (Pubitemid 47072063)
31. J. Weiss, M. Herzog, S. König, C.H. Storch, N. Ketabi-Kiyanvash, and W.E. Haefeli Induction of multiple drug transporters by efavirenz J Pharmacol Sci 109 2009 242 250
32. A.D. Mottino, T. Hoffman, L. Jennes, and M. Vore Expression and localization of multidrug resistant protein mrp2 in rat small intestine J Pharmacol Exp Ther 293 2010 717 723
33. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J Biol Chem 193 1951 265 275
34. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C. Pijnenborg, and A.H. Schinkel Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues Cancer Res 61 2001 3458 3464 (Pubitemid 32695041)
35. C. MacLean, U. Moenning, A. Reichel, and G. Fricker Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in male and female rats Drug Metab Dispos 36 2008 1249 1254 (Pubitemid 351929307)
36. S.K. Rabindran, D.D. Ross, L.A. Doyle, W. Yang, and L.M. Greenberger Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein Cancer Res 60 2000 47 50 (Pubitemid 30058728)
37. C.I. Ghanem, A. Arias, A. Novak, G.D. Carpini, S. Villanueva, and A.G. Blazquez Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line Biochem Pharmacol 81 2010 244 250
38. N. Berruet, S. Sentenac, D. Auchere, F. Gimenez, R. Farinotti, and C. Fernandez Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats J Pharm Pharm Sci 8 2005 226 234 (Pubitemid 41519136)
39. E. Störmer, L.L. von Moltke, M.D. Perloff, and D.J. Greenblatt Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture Pharm Res 19 2002 1038 1045 (Pubitemid 34804248)
40. J. Burhenne, A.K. Matthée, I. Pasáková, C. Röder, T. Heinrich, and W.E. Haefeli No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment Antimicrob Agents Chemother 54 2010 4185 4191
41. G. Dirson, C. Fernandez, P. Hindlet, F. Roux, M. German-Fattal, and F. Gimenez Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier Pharm Res 23 2006 1525 1532 (Pubitemid 43993816)
42. C. Ozvegy, A. Váradi, and B. Sarkadi Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation J Biol Chem 277 2002 47980 47990 (Pubitemid 35470743)
43. A. Telbisz, M. Müller, C. Ozvegy-Laczka, L. Homolya, L. Szente, and A. Váradi Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter Biochim Biophys Acta 1768 2007 2698 2713 (Pubitemid 350081032)
44. http://www.unaids.org/globalreport/Global-report.htm, 2010.